Uppsala expansion strengthens diagnostics capacity to meet global demand

Thermo Fisher Scientific has opened an 8,000 m² distribution and labelling centre in Uppsala, Sweden, designed to strengthen global supply chains for immunodiagnostic tests used in the diagnosis of allergic and autoimmune diseases.

The $18 million facility expands the company’s capacity to meet growing demand for in vitro diagnostic (IVD) testing, supporting conditions that affect an estimated two billion people worldwide. By integrating automated storage, scanning and labelling systems, the centre aims to improve accuracy, traceability and operational efficiency across high-volume diagnostic workflows.

The new site builds on Uppsala’s long-established role as a hub for immunodiagnostics research, development and manufacturing, reinforcing the region’s position within Thermo Fisher Scientific’s global diagnostics network.

Allergic and autoimmune conditions continue to drive rising demand for reliable and scalable diagnostic solutions, as healthcare systems place increasing emphasis on early and accurate disease detection.

“This investment in our distribution and labelling centre reflects our long-term growth strategy in Sweden and our commitment to meeting future global demand,” said Martin Kjellsson, Site Leader for Thermo Fisher Scientific’s immunodiagnostics business in Uppsala. “It strengthens our logistics capabilities and positions us to scale for future volumes while maintaining high-quality products and service.”

“Our immunodiagnostics business is focused on enabling patients around the world to receive timely and accurate diagnoses for allergic and autoimmune diseases,” said Santhosh Nair, President of Thermo Fisher Scientific’s immunodiagnostics business. “This investment in Uppsala reflects our continued commitment to innovation and operational excellence.”

The facility forms part of Thermo Fisher Scientific’s wider global expansion in diagnostics infrastructure, supporting increased production and distribution capacity across its immunodiagnostics portfolio.

More information online